These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37362161)

  • 1. A case of hyperphosphatemic familial tumoral calcinosis due to maternal uniparental disomy of a
    Nishimura-Kinoshita N; Ohata Y; Sawai H; Izawa M; Takeyari S; Kubota T; Omae Y; Ozono K; Tokunaga K; Hamajima T
    Clin Pediatr Endocrinol; 2023; 32(3):161-167. PubMed ID: 37362161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
    Rafaelsen S; Johansson S; Ræder H; Bjerknes R
    BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel homozygous variant in exon 10 of the
    Dayal D; Gupta S; Kumar R; Srinivasan R; Lorenz-Depiereux B; Strom TM
    Intractable Rare Dis Res; 2021 Feb; 10(1):55-57. PubMed ID: 33614378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
    Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
    Ito N; Fukumoto S
    Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
    Mahjoubi F; Ghadir M; Samanian S; Heydari I; Honardoost M
    J Endocrinol Invest; 2020 Aug; 43(8):1125-1130. PubMed ID: 32125652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
    Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
    Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
    Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
    J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
    Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
    Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
    Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two novel mutations in the
    Sun L; Zhao L; Du L; Zhang P; Zhang M; Li M; Liu T; Ye L; Tao B; Zhao H; Liu J; Ding X
    Bone Res; 2016; 4():16038. PubMed ID: 27867679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
    Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
    J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.
    Boyce AM; Lee AE; Roszko KL; Gafni RI
    Front Endocrinol (Lausanne); 2020; 11():293. PubMed ID: 32457699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
    Finer G; Price HE; Shore RM; White KE; Langman CB
    Am J Med Genet A; 2014 Jun; 164A(6):1545-9. PubMed ID: 24668887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
    Ichikawa S; Sorenson AH; Austin AM; Mackenzie DS; Fritz TA; Moh A; Hui SL; Econs MJ
    Endocrinology; 2009 Jun; 150(6):2543-50. PubMed ID: 19213845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.
    Sowaity ZA; Saleem JY; Sabooh TN; Dukmak ON; Abu Al-Saoud SY
    Cureus; 2024 Mar; 16(3):e55575. PubMed ID: 38576700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
    Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
    J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel
    Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.